Search

everythinglearnresearchcommunity

for

Search:↓

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ixekizumab has known and some unexpected side effects.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Efalizumab can cause unexpected excessive hair growth.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Ixekizumab effectively treats generalized pustular psoriasis.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.

Dupilumab effectively treats severe skin issues in a rare genetic disorder.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Anti-CD19 therapy may help treat SLE and NMOSD.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Promising cancer treatments were found, but the manufacturer closed.

17β-estradiol can reduce inflammation in the skin.